Ghiaseddin, A., Reardon, D., Massey, W., Mannerino, A., Lipp, E., Herndon, J., … Peters, K. (2015). Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. In Journal of Clinical Oncology (Vol. 33, pp. 104s-104s). McCormick Place, Chicago, IL: American Society of Clinical Oncology.

Ghiaseddin, Ashley, David Reardon, Woody Massey, Alexandra Mannerino, Eric Lipp, James Herndon, Frances McSherry, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” In Journal of Clinical Oncology, 33:104s-104s. American Society of Clinical Oncology, 2015.

Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp E, Herndon J, et al. Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology; 2015. p. 104s-104s.

Ghiaseddin, Ashley, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” Journal of Clinical Oncology, vol. 33, no. 15s, Part I of II, American Society of Clinical Oncology, 2015, pp. 104s-104s.

Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp E, Herndon J, McSherry F, Desjardins A, Randazzo D, Vlahovic G, Friedman H, Peters K. Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology; 2015. p. 104s-104s.